NCT06546267 Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
| NCT ID | NCT06546267 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2022-02-14 |
| Primary Completion | 2026-02-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2022-02-14 with a primary completion date of 2026-02-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high, and very high-risk prostate cancer, or with biochemical, lymph node, or oligometastatic recurrence treated between 2004 and 2024. Approved by Ethics Committee of IRCCS San Raffaele Hospital Approval Number: 187/INT/2021, 03/02/2022 Amendment approved by Ethics Committee 1, Lombardy Region Approval number CET Em. 194-2024, 22/05/2024
Eligibility Criteria
Inclusion Criteria: * Prostate cancer patients, \> 18 years old, treated with IGRT, IMRT, SBRT Exclusion Criteria: * other tumors * \> 95 years old
Contact & Investigator
Nadia G Di Muzio, Prof
PRINCIPAL INVESTIGATOR
IRCCS San Raffaele, Milan
Frequently Asked Questions
Who can join the NCT06546267 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 95 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06546267 currently recruiting?
Yes, NCT06546267 is actively recruiting participants. Contact the research team at fodor.andrei@hsr.it for enrollment information.
Where is the NCT06546267 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06546267 clinical trial?
NCT06546267 is sponsored by IRCCS San Raffaele. The principal investigator is Nadia G Di Muzio, Prof at IRCCS San Raffaele, Milan. The trial plans to enroll 2,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.